Solventum Corp (SOLV): Capital Expenditures

Annual figures by period end, from SEC filings.

$379.00M

Year ended 2025-12-31

$327.00M

Trailing 12 months to 2026-06-30

+14.7%

3-year compound annual growth

2022-12-31 Capital Expenditures (USD) 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$379.00M	-0.3%	2026-02-27, From 2025-01-01
2024-12-31	$380.00M	+31.0%	2026-02-27, From 2024-01-01
2023-12-31	$290.00M	+15.5%	2026-02-27, From 2023-01-01
2022-12-31	$251.00M	n/a	2025-02-28, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
Solventum Corp (SOLV)	2025-12-31	$379.00M	-0.3%
Baxter International Inc (BAX)	2025-12-31	$513.00M	+15.0%
ResMed Inc (RMD)	2026-06-30	$156.28M	+73.9%
Dexcom Inc (DXCM)	2025-12-31	$363.50M	+1.3%
Boston Scientific Corp (BSX)	2025-12-31	$876.00M	+10.9%
Becton Dickinson & Co (BDX)	2025-09-30	$760.00M	+4.8%
MiniMed Group, Inc. (MMED)	2026-04-24	$223.00M	+15.5%
West Pharmaceutical Services Inc (WST)	2025-12-31	$285.90M	-24.2%
Globus Medical Inc (GMED)	2025-12-31	$164.68M	+42.7%

Compare SOLV, BAX, RMD, DXCM side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗